Full-Time

Histology Associate II

Confirmed live in the last 24 hours

Veracyte

Veracyte

501-1,000 employees

Develops genomic tests for cancer diagnosis

Compensation Overview

$32 - $36/hr

+ Bonus + Incentives + Restricted Stock Units

Mid

San Diego, CA, USA

Category
Diagnostics & Laboratory Professionals
Medical, Clinical & Veterinary
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • High school diploma required; a four-year degree in life sciences is preferred
  • 2-5 years’ experience in a laboratory setting
  • Excellent verbal and written communication skills
  • Ability to solve problems and collaborate with peers
  • Basic computer skills, including data entry and use of laboratory information systems
  • The ability to navigate efficiently through, or have familiarity with, various laboratory information systems (LIS) and have proficiency in Microsoft Office products (Excel, Word, Access and PowerPoint)
  • Ability to follow detailed instructions and maintain accurate records
  • Ability to work with no supervision and exercise good judgment
Responsibilities
  • The Histology Associate II is responsible for specimen reconciling, sample return, sample capture, and ensuring quality throughout the pre-analytical processes; other duties as assigned
  • Multi-tasking efficiently, maintaining flexibility, and working as a team player will be critical while processing samples according to multiple workflows and maintaining established turnaround times
  • Capable of identifying specimen processing problems that may adversely affect the reporting of test results and immediately notify the supervisor
  • Complete other related administrative duties, including copying, filing and data entry
  • Maintain supply inventory logs- materials and laboratory supplies
  • Take ownership and accountability of ensuring the highest quality of internal/external customer service
  • Assist in the training and implementation of departmental standard operation procedures
  • Participates in projects, research, and validation activities as assigned
  • Handling and disposing of hazardous non-hazardous materials
  • Perform all duties according to guidelines outlined within the quality systems
  • Compliant with company policies, procedures, safety requirements and regulations
Desired Qualifications
  • A four-year degree in life sciences is preferred

Veracyte specializes in cancer diagnostics by developing advanced genomic tests that assist in the early detection and diagnosis of various cancers. Their tests analyze genetic information from non-invasive samples, such as nasal swabs or tissue biopsies, providing crucial insights into the presence and progression of cancer. This allows healthcare providers, including hospitals and clinics, to make informed treatment decisions tailored to individual patients. Veracyte differentiates itself from competitors by focusing on non-invasive testing methods and continuously investing in research to expand its product offerings. The company's goal is to improve patient outcomes and enhance the efficiency of medical resources through accurate cancer diagnostics.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • AI integration enhances accuracy and speed of Veracyte's cancer detection tests.
  • Rising telemedicine adoption boosts demand for Veracyte's remote diagnostic solutions.
  • Collaborations with pharmaceutical firms accelerate development of companion diagnostics.

What critics are saying

  • Competition from Guardant Health and Exact Sciences may impact Veracyte's market share.
  • Rapid genomic sequencing advancements require continuous R&D investment from Veracyte.
  • Changes in U.S. healthcare reimbursement policies could affect Veracyte's test pricing.

What makes Veracyte unique

  • Veracyte specializes in non-invasive genomic tests for early cancer detection.
  • The Decipher Prostate classifier aids in assessing prostate cancer prognosis.
  • Veracyte's nasal swab test improves early lung cancer risk assessment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Stock Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
ETF Daily News
Mar 21st, 2025
Proficio Capital Partners LLC Invests $1.18 Million in Veracyte, Inc. (NASDAQ:VCYT)

Proficio Capital Partners LLC invests $1.18 million in Veracyte, Inc. (NASDAQ:VCYT).

Stock Titan
Mar 19th, 2025
Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

Veracyte (VCYT) announced multiple abstract presentations at the 40th Annual European Association of Urology Congress (EAU25) in Madrid, Spain, showcasing the clinical performance and utility of its Decipher tests for prostate and bladder cancer.

MLO Online
Feb 17th, 2025
New Data at ASCO demonstrates the performance and clinical utility of Veracyte's Decipher Prostate and Decipher Bladder tests

Veracyte, Inc. announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) demonstrate the performance and clinical utility of its Decipher Prostate and Decipher Bladder tests to help guide treatment for patients with prostate and bladder cancer.

MarketBeat
Dec 21st, 2024
HighTower Advisors LLC Makes New Investment in Veracyte, Inc. (NASDAQ:VCYT)

HighTower Advisors LLC makes new investment in Veracyte, Inc. (NASDAQ:VCYT).

Inside Precision Medicine
Oct 3rd, 2024
Veracyte's RNA Genetic Test Predicts Black Men's Aggressive Prostate Cancer

That's why Veracyte is testing their Decipher Prostate Genomic Classifier, an AI-based transcriptome genetic test that was developed using primarily White American males, on Black African American males to see if it offers clinicians an improvement over clinical factors alone in guiding prostate cancer treatment decisions.